MetaCap

Cue Biopharma (CUE) vs Filana Therapeutics (FLNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cue Biopharma (CUE) has outperformed Filana Therapeutics (FLNA) over the past year, losing 76.8% versus a loss of 77.7%. Over five years, FLNA leads with a -98.9% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $32.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUE-76.75%FLNA-77.66%
+122%+13%-95%
Nov 21, 20251 yearNov 20, 2026
CUE-99.07%FLNA-98.79%
+10%-47%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUE versus FLNA key metrics
MetricCUEFLNA
Share price$4.15$0.6413
Market cap$34.69M$32.26M
1-day change-7.78%+14.52%
YTD return-54.64%-67.61%
1-year return-76.75%-77.66%
5-year return-98.92%-98.85%
EPS (TTM)$-27.80$-0.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.47M—
Revenue growth (YoY)+195.75%—
Net income (latest FY)$-26.60M$-90.97M
Operating margin-96.67%—
Net margin-96.85%—
52-week high$45.50$3.45
52-week low$2.83$0.39
Distance from 52-week high-90.88%-81.41%
Analyst consensusnonenone
Avg. price target upside+2020.48%+913.57%
Average volume567.02K2.09M
Shares outstanding8.36M50.30M
Employees2917
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Filana Therapeutics

FLNA stock →

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

CUE vs FLNA FAQ

Which is bigger, Cue Biopharma or Filana Therapeutics?

Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $32.26M for Filana Therapeutics (FLNA).

Which stock has performed better over the past year, CUE or FLNA?

CUE returned -76.75% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.

Are Cue Biopharma and Filana Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons